Autolus Therapeutics AUTL 深 滬
等待開盤 11-05 09:30:00 美东时间
1.41
-0.150
-9.62%
華盛通- 最 高1.535
- 今 開1.49
- 成交量 197.12万股
- 最 低 1.40
- 昨 收 1.56
- 總市值 3.75亿
- 52周最高 3.45
- 市盈率 靜 --
- 換手率 0.74%
- 52周最低 1.105
- 委 比 3.12%
- 總股本 2.66亿
- 歷史最高 53.24
- 量 比 1.06
- 振 幅 8.65%
- 歷史最低 1.105
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics宣布其CAR-T细胞疗法obe-cel在治疗严重难治性红斑狼疮、儿童B-ALL及成人复发/难治性B-ALL方面显示积极临床结果，并在ASCO年会上展示相关数据。
11-03 14:05
Autolus' Obe-cel Shows 83% Remission Rate in Early Lupus Study, FDA-Backed Phase 2 Next
Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that follow-up data from
10-27 19:10
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
10-20 17:41
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
Autolus Therapeutics initiates its Phase 1 BOBCAT trial for obe-cel in patients with progressive multiple sclerosis (PMS), with the first patient dosed at University College London Hospitals NHS Foundation Trust (UCLH). Obe-cel, a CAR T cell therapy targeting B cells, aims to address autoimmune and CNS inflammatory pathways linked to PMS progression. The trial will assess safety, tolerability, and preliminary efficacy in up to 18 patients. Dr. Wa...
10-20 11:00
Autolus Therapeutics Announces Online Publication Of An Abstract For The Upcoming ACR Convergence 2025 Conference. The Company Will Present A Poster With Updated Follow-up Data From Its Carlysle Study In Patients With Severe Refractory Systemic Lupus Erythematosus
Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of
09-16 20:10
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
Autolus Therapeutics announced the online publication of an abstract for their ACR Convergence 2025 poster presentation, showcasing updated data from the CARLYSLE study on obe-cel for severe refractory systemic lupus erythematosus (srSLE). The Phase I study demonstrates a manageable safety profile with no dose-limiting toxicities or severe CRS/ICANS, alongside reductions in SLEDAI-2K scores and clinical benefit in all patients, including complete...
09-16 12:05
Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $5
Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target from $6 to $5.
08-13 20:50
Autolus Therapeutics shares are trading lower. The company reported Q2 financial results.
Autolus Therapeutics shares are trading lower. The company reported Q2 financia...
08-13 00:56
Autolus Therapeutics Q2 EPS $(0.18) Beats $(0.24) Estimate, Sales $20.923M Beat $12.905M Estimate
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 18.18 percent increase over losses of $(0.22) per share from
08-12 19:05
